EN DE
Watch Telcon Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Telcon Inc (200230) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Telcon Inc stock KRW 3,978, price KRW 1,765, upside +125.4%, quality 43 out of 100. Rating: strongly undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7200230001

TI Telcon Inc logo Thin data Nov 16, 2026

Telcon Inc

200230 · KQ

Cheap (56% below fair value), but weak company and falling price: meets 1 of 3 rules.

Follow free in the weekly email
Fair value 3,978 KRW · Strongly undervalued 
Low debt 
Generates free cash flow 
Even on cautious assumptions the value is 118% above the price (3,853 KRW). 
Quality 43/100 
Mixed Growth (revenue 5y +5.4 %/yr in KRW) 
Mixed vs. peers (6/11) 
Falling price (downtrend) 
Loss-making · -28.3% net margin (TTM) 
Narrow moat 18/100
Thin data 
⚠ Dilution
Watch Telcon Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

140,723 KRW 1,765 KRW Fair Value 3,978 KRW May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,765 KRW – 140,723 KRW · fair‑value band 3,853 KRW – 4,088 KRW · the 1,765 KRW price screens below the 3,978 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Telcon in your weekly email

Every Wednesday you see whether Telcon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals.

Show moreShow less

The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is headquartered in Yongin-si, South Korea.

Stock analysis

Telcon Inc (200230) currently trades at 1,765 KRW, while our model-based Fair Value estimate is 3,978 KRW, implying the stock looks roughly 56% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 17,805 KRW per share, and 10 of the 13 models we run sit above the 1,765 KRW price.

Bear case: the Asset-Based group reads lowest at 1,340 KRW, and 3 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: 3,853 KRW (bear) to 4,088 KRW (bull), the price of 1,765 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Telcon Inc reported revenue of 43.2B KRW in FY2025 versus 37.8B KRW in FY2021, a compound +3.3%/yr. Reported net income was −11.5B KRW in FY2025.

Key figures

Market cap 12.6B KRW (≈ $9.5M) Micro · P/S ratio 0.23 · EPS (TTM) −2,206 KRW · Net margin −28.3% · Return on equity −32.7% · Return on assets (EBIT) −4.2% (5-year average) · Operating margin −2.8% · Revenue (TTM) 61.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 84% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 125%, 200230 screens cheaper than that median.

Fair Value models

Bear 3,853 KRW Fair Value 3,978 KRW Bull 4,088 KRW
Price 1,765 KRW · Upside +125.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 12,848 KRW 18,121 KRW 26,297 KRW 80
Growth DCF 13,008 KRW 17,671 KRW 24,455 KRW 79
5Y EBITDA Exit 12,948 KRW 18,707 KRW 25,407 KRW 76
All 13 models by family
DCF Models
FCF DCF 12,848 KRW 18,121 KRW 26,297 KRW 80
5Y Revenue Exit 7,393 KRW 8,280 KRW 9,250 KRW 74
5Y EBITDA Exit 12,948 KRW 18,707 KRW 25,407 KRW 76
10Y Revenue Exit 9,233 KRW 10,510 KRW 11,970 KRW 68
10Y EBITDA Exit 12,828 KRW 17,805 KRW 24,414 KRW 69
Earnings-Based
EPV 4,532 KRW 4,680 KRW 4,810 KRW 74
Multiples
EV/EBIT 945.67 KRW 1,550 KRW 2,153 KRW 64
EV/EBITDA 9,614 KRW 13,108 KRW 16,601 KRW 67
EV/Revenue 49.89 KRW 442.42 KRW 834.95 KRW 47
Asset-Based
NCAV (Graham) 884.44 KRW 1,340 KRW 1,675 KRW 54
Growth DCF
Growth DCF 13,008 KRW 17,671 KRW 24,455 KRW 79
Rev-Margin DCF 7,393 KRW 8,435 KRW 9,700 KRW 74
Economic Profit
ROIC Compounder 4,532 KRW 4,680 KRW 4,810 KRW 72

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 43
Do the profits arrive as real cash?
Financial strength 48
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic). Over 10 years: +4.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.7% (2019) → −0.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +9.2% a year for the price.

Watch 200230, get fair value alerts →

Compare Telcon Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside +125.4% · Top 25%
Profitability
Return on assets −7.3% · Bottom 25%
Net margin (12 months) −28.3% · Bottom 25%
Operating margin (12 months) −2.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 188.5% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.12× · Cheapest 25%
P/S (12 months) 0.20× · Cheapest 25%
Price / free cash flow (fiscal year) 9.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 20
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs 200230
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs 200230
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs 200230
Haleon plc HLN $9.08 $8.47 −7% vs 200230
Merck KGaA MRK €148.40 €108.83 −27% vs 200230
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs 200230
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs 200230
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs 200230
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs 200230
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs 200230

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Telcon Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Telcon Inc Fair Value". https://www.fairvalue-calculator.com/stock/200230

Frequently asked questions

Is Telcon Inc (200230) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of 3,978 KRW versus a price of 1,765 KRW, about +125% upside (undervalued).
What is the fair value of 200230?
Our model-based fair value for Telcon Inc is 3,978 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 1,765 KRW.
What is the quality score of 200230?
Telcon Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Telcon Inc (200230)?
We do not set a price target; the yardstick is the fair value of 3,978 KRW (as of Nov 16, 2026) from 13 valuation models. Cautious scenario 3,853 KRW, optimistic scenario 4,088 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Telcon Inc stock forecast for 2026?
Our models put fair value at 3,978 KRW, about +125% upside versus a price of 1,765 KRW (undervalued). Cautious scenario 3,853 KRW, optimistic scenario 4,088 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Telcon Inc (200230)?
Telcon Inc reported trailing-twelve-month revenue of about 61.8B KRW (latest available figure, as of Nov 16, 2026).
What growth is priced into Telcon Inc (200230)?
For today's price to be fair in a discounted-cash-flow model, Telcon Inc would have to grow free cash flow by 11.5 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 5.4 % per year. As of Nov 16, 2026.
What discount rate (WACC) does the fair value of 200230 use?
Our models discount Telcon Inc at 8.9 %: a base by market capitalisation (nano), damped by beta 0.38, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Telcon Inc that is +11.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Telcon Inc (200230) delivered so far?
Over the past 5 years revenue at Telcon Inc grew 5.4 % a year. The price currently implies free-cash-flow growth of +11.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Telcon Inc (200230) growing?
The median revenue growth in the sector is +12.1 % a year. That is the yardstick for the growth priced into Telcon Inc (+11.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Telcon Inc (200230)?
The free-cash-flow yield on the price is 11.14 %: that much free cash flow Telcon Inc produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Telcon Inc (200230)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Telcon Inc it is 3,978 KRW per share (as of Nov 16, 2026), against a price of 1,765 KRW. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Telcon Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 200230 trades below its calculated fair value: price 1,765 KRW, fair value 3,978 KRW, a gap of about +125% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 200230?
No. The price is what the market pays today (1,765 KRW); the fair value is what the company's own numbers justify (3,978 KRW). For Telcon Inc the two are 2,213 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Telcon Inc worth?
The market values Telcon Inc at about 12.6B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 1,765 KRW; our models calculate a fair value of 3,978 KRW per share.
What do the bullish and bearish scenarios say about 200230?
Our models span a range for Telcon Inc: cautious scenario 3,853 KRW, base 3,978 KRW, optimistic 4,088 KRW per share (as of Nov 16, 2026, price 1,765 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Telcon Inc (200230)?
Balance-sheet figures for Telcon Inc (as of Nov 16, 2026): return on equity −32.7%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 200230 from its 52-week high?
Telcon Inc trades at 1,765 KRW, about 84% below its 52-week high of 11,190 KRW and at the low of 1,765 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 3,978 KRW is for.
Which stocks are comparable to Telcon Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Telcon Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 1,765 KRW, calculated fair value 3,978 KRW (+125%), Quality Score 43/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 200230 calculated?
We run Telcon Inc through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of 3,978 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Telcon Inc currently trades 56% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Telcon Inc (200230)?
The closing price on Nov 19, 2026 was 1,765 KRW. Our model-based fair value is 3,978 KRW, about +125% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Telcon Inc right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (3,853 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (3,853 KRW to 4,088 KRW), unusually little disagreement for a valuation.

Key figures of Telcon Inc

How large is the market capitalisation of Telcon Inc (200230)?
The market capitalisation of Telcon Inc is 12.6B KRW (≈ $9.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Telcon Inc (200230)?
The price-to-sales ratio of Telcon Inc is 0.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Telcon Inc (200230)?
Earnings per share at Telcon Inc are −2,206 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Telcon Inc (200230)?
The net margin of Telcon Inc is −28.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Telcon Inc (200230)?
The return on equity (ROE) of Telcon Inc is −32.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Telcon Inc (200230)?
On an EBIT basis the return on assets of Telcon Inc is −4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Telcon Inc (200230)?
The operating margin of Telcon Inc is −2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Telcon Inc (200230)?
Revenue at Telcon Inc is growing 189% versus a year earlier (3y avg +15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Telcon Inc (200230)?
Earnings per share at Telcon Inc are growing 952% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Telcon Inc (200230) carry?
The net debt of Telcon Inc is 6.2B KRW (fiscal year 2025, ≈ 4.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Telcon Inc in the live analysis

One click puts Telcon Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.